sirona biochem corp (SBM:Venture)
sirona biochem corp (SBM) Snapshot
|
Open
C$0.10
|
Previous Close
C$0.11
|
|
|
Day High
C$0.11
|
Day Low
C$0.10
|
|
|
52 Week High
01/9/13 - C$0.15
|
52 Week Low
09/11/12 - C$0.03
|
|
|
Market Cap
9.9M
|
Average Volume 10 Days
137.1K
|
|
|
EPS TTM
C$-0.04
|
Shares Outstanding
94.1M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
sirona biochem corp (SBM) Related Businessweek News
No Related Businessweek News Foundsirona biochem corp (SBM) Details
Sirona Biochem Corp., a development stage company, engages in the discovery and development of novel drug compounds. The company specializes in the development of carbohydrate-based molecules that have applications in therapeutics, cosmeceuticals, and biological ingredients. It is developing a Sodium Glucose Transporter (SGLT) inhibitor, which is in a preclinical study for Type 2 diabetes and obesity; and a cancer vaccine antigen. The company is also developing a depigmenting agent to lighten and evenly tone skin; and anti-aging cosmetic agents, which could be used to maintain and enhance skin vitality. In addition, it is developing IPGMim, a biological inducer for the production of recombinant protein by Escherichia coli; and glycopeptides as an adjuvant to be used for organ, tissue, and cells preservation. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was founded in 2006 and is headquartered in Vancouver, Canada.
sirona biochem corp (SBM) Top Compensated Officers
sirona biochem corp (SBM) Key Developments
Sirona Biochem Corp. announced it has completed the set of industry-standard cosmetic safety tests for both skin lightening compounds, TFC-849 and TFC-723. The final two safety tests studied phototoxicity and skin irritation in accordance with the regulatory methods of the European Centre for the Validation of Alternative Methods (ECVAM) and the Organization for Economic Co-operation and Development (OECD). The successful completion of the safety tests for both compounds means that Sirona Biochem will be releasing two skin lightening compounds for national, multi-national and global licensing agreements. The phototoxic potential of TFC-849 and TFC-723 was evaluated at a concentration range 0 to 1000 µg/ml for 1 hr on fibroblast cultures, exposed to the high non-cytotoxic UVA irradiation dose (5 J/cm²). Fibroblasts' viability was assessed using the neutral red uptake method and compared in both irradiated and non-irradiated cultures. Neither compound (TFC-849 or TFC-723) showed phototoxicity in the concentration range tested. The irritant potential of TFC-849 and TFC-723 was evaluated on reconstituted human epithelium (RHE) at concentrations 0.5%, 2.5% and 5% (w/v). The RHE viability was assessed using an MTT assay and both depigmenting agents, TFC-849 and TFC-723, showed no skin irritation in the concentration range studied.
Sirona Biochem Corp. filed its Annual on Feb 28, 2013 for the period ending Oct 31, 2012. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Sirona Biochem Corp., Annual General Meeting, Apr 05, 2013. Location: Suite 1128, 789 West Pender Street.
| Recently Viewed | |||
| SBM:CN | C$0.11 CAD | 0.00 | |
| Company | Last | Change | |
| No competitor information is available for SBM. | |||
| View Industry Companies | |||
Industry Analysis
SBM
Industry Average
| Valuation | SBM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 5.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact SIRONA BIOCHEM CORP, please visit www.sironabiochem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.







